Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-10-10
2006-10-10
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07119118
ABSTRACT:
A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
REFERENCES:
patent: 5252333 (1993-10-01), Horrobin
patent: 5589508 (1996-12-01), Schlotzer et al.
patent: 5837731 (1998-11-01), Vaddadi
patent: 5840944 (1998-11-01), Furihata et al.
patent: 6555700 (2003-04-01), Horrobin et al.
patent: 0302482 (1989-02-01), None
patent: 0 460 917 (1991-12-01), None
patent: 0 606 012 (1994-07-01), None
patent: 0 610 506 (1994-08-01), None
patent: 2148713 (1985-06-01), None
patent: 2 229 363 (1990-09-01), None
patent: 04 182426 (1992-06-01), None
patent: WO 97 39759 (1997-10-01), None
patent: WO98/16216 (1998-04-01), None
patent: WO 99 29316 (1999-06-01), None
Malcolm Peet et al, Phospholipid Spectrum Disorder in Psychiatry pp. 1-19, 1999.
Brian E. Leonard, Fundamentals of Psychopharmacology, pp. 186-187, 1997.
Diagnostic and Statistical Manual of Mental Disorders, 4thEd., published by the American Psychiatric Assoc., p. 285 (1995).
Martin A. Samuels, M.D. et al. Office Practice of Neurology, Chapter 122, Huntington's Disease, pp. 654-655 (1996).
S. Leucht et al, Schizophrenia Research, vol. 35, “Efficacy and extrapyramidal side -effects . . . ”, pp. 51-68, 1999.
Nina Willumsen et al, Biochimica et Biophysica Acta, vol. 1369, “On the effect of 2-deuterium- . . . ”, pp. 193-203, 1998.
E. Mayatepek et al, The Lancet, vol. 352, “Leukotriene C4-synthesis deficiency . . . ”, pp. 1514-1517, Nov. 7, 1998.
Atsushi Yamashita et al, J. Biochem., vol. 122, No. 1, “Acyl-transferases and Transacylases . . . ”, pp. 1-16, 1997.
Yang Cao et al, Genomics, vol. 49, “Cloning, Expression, and Chromosomal Localization . . . ”, pp. 327-331, 1998.
Monica Piccini et al, Genomics, vol. 47, “FACL4, a New Gene En-coding Long-Chain Acyl-CoA . . . ”, pp. 350-358, 1998.
Michael J. Finnen et al, Biochemical Society Trans., “Purifi-cation and characterisation . . . ”, p. 19, 1991.
Andrew L. Stoll et al. Arch. Gen. Psychiatry, vol. 56, “Omega 3 Fatty Acids in Bipolar Disorder”, pp. 407-412, May 1999.
B. Puri et al, Archives of General Psychiatry, No. 55, “Sustain-ed remission of positive and . . . ”, pp. 188-189, 1998.
Stephen T. Warren, Science, vol. 271, “The Expanding World of Trinucleotide Repeats”, pp. 1374-1375. Mar. 8, 1996.
Victor O. Ona et al, NATURE, vol. 399, “Inhibition of caspase-1 slows disease progression . . . ”, pp. 263-267, May 20, 1999.
Philippe Dijan et al, Proc. Natl. Acad. Sci., vol. 93, “Codon repeats in genes associated . . . ”, pp. 417-421, Jan. 1996.
M. Flint Beal, MD, Annals of Neurology, vol. 38, No. 3, “Aging, Energy, and Oxidative Stress in . . . ”, pp. 357-366, Sep. 1995.
S. L. McElroy et al., “Clozapine in the Treatment of Psychotic Mood Disorders, Schizoaffective Disorder, and Schizophrenia”, Journal of Clinical Psychiatry, vol. 52, No. 10, Oct. 1991, pp. 411-414.
K.L. Black et al., “Effect of intravenous eicosapentaenoic acid on cerebral blood flow, edema, and brain prostaglandins in ischemic gerbils”, Prostaglandins (1984), 28(4), pp. 545-546.
M. Sato et al., “General Pharmacological Studies on 5 8 11 14 17 Eicosapentaenoic Acid Ethyl Ester EPA-E”, Folia Pharmacol JPN, (1989) 94 (1), 35-48.
N. Madhavi et al., “Effect of n-6 and n-3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro”, Cancer Letters, vol. 84, No. 1, 1994, pp. 31-41.
Katsuya Yamazaki et al., “Changes in fatty acid composition in rat blood and organs after infusion of eicosapentaenoic acid ethyl ester”, Biochim. Biophys. ACTA (1992), 1128(1), 35-43.
Toshihiro Yoshimura et al, Effects of highly purified eicosapentaenoic acid on plasma beta thromboglobulin level and vascular reactivity to angiotensin II, Artery (1987) 14(5) pp. 295-303.
Masaharu Urakaze et al., “Infusion of emulsified trieicosapentaenoylglycerol into rabbits. The effects on platelet aggregation, polymorphonuclear leukocyte adhesion, and fatty acid composition in plasma and platelet phosphollpids”, Thromb. Res. (1986) 44(5), pp. 673-682.
Ikuyoshi Watanabe et al., “Usefulness of EPA-E (eicosapentaenoic acid ethyl ester) in preventing neointimal formation after vascular injury”, Kokyu to Junkan (1994), 42(7), pp. 673-677.
S. Shah et al., “Eicosapentaenoic Acid (EPA) as an Adjunct in the Treatment of Schizophrenia”, Schizophrenia Research, vol. 29, No. 1/02, Jan. 1998.
Peet Malcolm
Vaddadi Krishna S
Jacobson & Holman PLLC
Laxdale Limited
Spivack Phyllis G.
LandOfFree
Highly purified ethyl EPA and other EPA derivatives for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Highly purified ethyl EPA and other EPA derivatives for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Highly purified ethyl EPA and other EPA derivatives for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3616039